You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

T/M-MPAL

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Induction Chemo, Acute T-Lymphocytic Leukemia, T-cell Lymphoblastic Lymphoma Leukemia Trial in Suzhou (Decitabine combined with

Recruiting
  • Induction Chemotherapy
  • +3 more
  • Decitabine combined with HAAG Regimen
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Jun 22, 2020

Diffuse Midline Glioma, H3 K27M-Mutant Trial in San Francisco (Cyclophosphamide, Fludarabine, Autologous Anti-H3.3K27M

Not yet recruiting
  • Diffuse Midline Glioma, H3 K27M-Mutant
  • San Francisco, California
    University of California, San Francisco
Aug 15, 2022

Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) Trial (Fludarabine (30 mg/m^2), Cyclophosphamide (500 mg/m^2), CRG-022

Not yet recruiting
  • Cancer
  • Relapsed/Refractory Large B-cell Lymphoma (LBCL)
  • Fludarabine (30 mg/m^2)
  • +2 more
  • (no location specified)
Jul 25, 2023

Hepatocellular Carcinoma, Liver Cancer, Adult, Liver Cell Carcinoma Trial (LioCyx-M, Lenvatinib)

Not yet recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • (no location specified)
Jan 4, 2022

MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Recruiting
  • Acute Lymphoblastic Leukemia
  • Large B-cell Lymphoma
  • Minneapolis, Minnesota
    Masonic Cancer Center at University of Minnesota
Nov 2, 2022

CNS Tumors, Atypical Teratoid/Rhabdoid Tumor, Diffuse Midline Glioma, H3 K27M-Mutant Trial in Memphis (B7-H3-CAR T cells)

Not yet recruiting
  • Central Nervous System Neoplasms
  • +6 more
  • B7-H3-CAR T cells
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Apr 18, 2023

Diffuse Midline Glioma, H3 K27M-Mutant Trial (GD2 CAR T cells)

Not yet recruiting
  • Diffuse Midline Glioma, H3 K27M-Mutant
  • GD2 CAR T cells
  • (no location specified)
Sep 15, 2022

Large B-cell Lymphoma, B-cell Lymphoma Trial in Houston (Magrolimab, Rituximab, CAR T leukapheresis)

Not yet recruiting
  • Large B-cell Lymphoma
  • B-cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jun 29, 2023

Soft Tissue Sarcoma, Bone Sarcoma Trial in Houston (Cyclophosphamide, attIL2-T cells)

Not yet recruiting
  • Soft Tissue Sarcoma
  • Bone Sarcoma
  • Houston, Texas
    M D Anderson Cancer Center
Nov 10, 2022

LANDscape MApping of Epitopes and T Cell Receptors for Selected

Recruiting
  • Solid Tumor
    • Toronto, Ontario, Canada
      Princess Margaret Cancer Centre
    Apr 21, 2022

    Lung Cancer Stage IV, EGFR T790M Trial in Seoul (Lazertinib)

    Not yet recruiting
    • Lung Cancer Stage IV
    • EGFR T790M
    • Seoul, MA, Korea, Republic of
      Samsung Medical Center
    Jan 26, 2023

    Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma Trial in Australia, United States (Prednisone, Vincristine,

    Recruiting
    • Acute Lymphoblastic Leukemia
    • Acute Lymphoblastic Lymphoma
    • Palo Alto, California
    • +6 more
    May 2, 2022

    Cancer Of Prostate Trial run by the National Cancer Institute (NCI) (M9241, Stereotactic Body Radiation Therapy (SBRT))

    Recruiting
    • Cancer Of Prostate
    • M9241
    • Stereotactic Body Radiation Therapy (SBRT)
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Feb 2, 2023

    Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell

    Active, not recruiting
    • Recurrent Anaplastic Large Cell Lymphoma
    • +10 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 30, 2023

    Epithelial Ovarian Cancer Trial in Shanghai (LCAR-M23 cells)

    Terminated
    • Epithelial Ovarian Cancer
    • LCAR-M23 cells
    • Shanghai, Shanghai, China
      Shanghai East Hospital
    Aug 15, 2022

    Multiple Myeloma, Smoldering Multiple Myeloma Trial in Boston (Ciltacabtagene Autoleucel, Cyclophosphamide, Fludarabine

    Not yet recruiting
    • Multiple Myeloma
    • Smoldering Multiple Myeloma
    • Ciltacabtagene Autoleucel
    • +2 more
    • Boston, Massachusetts
      Dana Farber Cancer Institute
    Mar 2, 2023

    Lymphomas, B-cell Lymphomas Trial in Houston (JV-213, Leukapheresis)

    Not yet recruiting
    • Lymphomas
    • B-cell Lymphomas
    • Houston, Texas
      The University of Texas M D Anderson Cancer Center
    Mar 6, 2023

    Post-operative Functional Disability in Unrecognized Cognitive

    Recruiting
    • Cognitive Impairment (CI)
      • Toronto, Ontario, Canada
      • +2 more
      Aug 19, 2022

      Metastatic Solid Tumor, Brain Metastases Trial in Houston (Trastuzumab emtansine, Tucatinib)

      Not yet recruiting
      • Metastatic Solid Tumor
      • Brain Metastases
      • Houston, Texas
        M D Anderson Cancer Center
      Dec 30, 2022

      CD8+ T-cell PET/CT Imaging in COVID-19 Patients

      Recruiting
      • Lymphopenia Due to COVID-19
      • +2 more
      • [89Zr]Df-IAB22M2C PET/CT scan
      • Nijmegen, Gelderland, Netherlands
        Radboud university medical center
      Jun 2, 2022

      Solid Tumor Trial in Houston (Single Injection of IVS-3001- Anti - HLA-G CAR-T cells, Fludarabine phosphate, Cyclophosphamide)

      Not yet recruiting
      • Solid Tumor
      • Single Injection of IVS-3001- Anti - HLA-G CAR-T cells
      • +3 more
      • Houston, Texas
        M D Anderson Cancer Center
      Jan 19, 2023

      Cardiomyopathy Using Cardiac MRI (AID-MRI)

      Not yet recruiting
      • Cardiomyopathies
        • Calgary, Alberta, Canada
        • +3 more
        Mar 30, 2023

        Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides Trial in United

        Recruiting
        • Folliculotropic Mycosis Fungoides
        • +7 more
        • Durvalumab
        • +2 more
        • Duarte, California
        • +3 more
        Jan 12, 2023

        Melanoma Stage III, Melanoma Stage IV Trial in Amsterdam (T-VEC)

        Recruiting
        • Melanoma Stage III
        • Melanoma Stage IV
        • Amsterdam, NH, Netherlands
          Antoni van Leeuwenhoek ziekenhuis
        Feb 11, 2022

        Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Grade 1

        Active, not recruiting
        • Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
        • +18 more
        • Anti-ICOS Monoclonal Antibody MEDI-570
        • +2 more
        • Duarte, California
        • +22 more
        Jan 18, 2023